Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism

Respiratory Medicine

Volumn 103, Issue 7, 2009, Pages 951-962

  Trow, Terence K ^a   Taichman, Darren B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pulmonary   (United States)

Author keywords

Endothelin; Endothelin receptor antagonists; Endothelin receptors; Pulmonary arterial hypertension

Indexed keywords

ACETYLCHOLINE; AMBRISENTAN; BOSENTAN; BSF 420627; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 6; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SELECTIVITY; HUMAN; HYPERTROPHY; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VASOCONSTRICTION;

ENDOTHELIAL CELLS; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR CROSS-TALK; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; UNITED STATES; VASOCONSTRICTION; VASODILATION;

EID: 67349277689     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.02.016     Document Type: Review

References (65)

1. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 13 (2006) 1417-1431
2. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 6163 (1988) 411-415
3. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 24 (1993) 1732-1739
4. Morelli S., Ferri C., Polettini E., et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99 3 (1995) 255-260
5. Li H., Elton T.S., Chen Y.F., et al. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 266 5 Pt 1 (1994) L553-L560
6. Clozel M., and Clozel J.P. Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther 250 3 (1989) 1125-1131
7. Yang Z.H., Buhler F.R., Diederich D., et al. Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol 13 Suppl. 5 (1989) S129-S131
8. Ito H., Hirata Y., Hiroe M., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 69 1 (1991) 209-215
9. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 83 2 (1989) 708-712
10. Yang Z., Krasnici N., and Luscher T.F. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100 1 (1999) 5-8
11. Muldoon L.L., Pribnow D., Rodland K.D., et al. Endothelin-1 stimulates DNA synthesis and anchorage-independent growth of Rat-1 fibroblasts through a protein kinase C-dependent mechanism. Cell Regul 1 4 (1990) 379-390
12. Cambrey A.D., Harrison N.K., Dawes K.E., et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 11 4 (1994) 439-445
13. Helset E., Lindal S., Olsen R., et al. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am J Physiol 271 4 Pt 1 (1996) L538-L546
14. Browatzki M., Schmidt J., Kubler W., et al. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95 2 (2000) 98-105
15. Filep J.G., Fournier A., and Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol 115 2 (1995) 227-236
16. Loesch A. Localisation of endothelin-1 and its receptors in vascular tissue as seen at the electron microscopic level. Curr Vasc Pharmacol 3 4 (2005) 381-392
17. Davie N., Haleen S.J., Upton P.D., et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165 3 (2002) 398-405
18. Abraham D.J., Vancheeswaran R., Dashwood M.R., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151 3 (1997) 831-841
19. Lutz J., Gorenflo M., Habighorst M., et al. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 37 4 (1999) 423-428
20. Bauer M., Wilkens H., Langer F., et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 9 (2002) 1034-1036
21. Dupuis J., Goresky C.A., and Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81 4 (1996) 1510-1515
22. Hirata Y., Emori T., Eguchi S., et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91 4 (1993) 1367-1373
23. Shichiri M., Kato H., Marumo F., et al. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30 5 (1997) 1198-1203
24. Clozel M., Breu V., Gray G.A., et al. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 22 Suppl. 8 (1993) S377-S379
25. Iglarz M., and Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 50 6 (2007) 621-628
26. Juergens U.R., Racke K., Uen S., et al. Inflammatory responses after endothelin B (ET(B)) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ET(B)-receptor antagonism. Pulm Pharmacol Ther (2008)
27. Cardozo A.M., D'Orleans-Juste P., Yano M., et al. Influence of endothelin ET(A) and ET(B) receptor antagonists on endothelin-induced contractions of the guinea pig isolated gall bladder. Regul Pept 69 1 (1997) 15-23
28. Fukuroda T., Ozaki S., Ihara M., et al. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol 113 2 (1994) 336-338
29. Liu J.J., Chen J.R., and Buxton B.F. Unique response of human arteries to endothelin B receptor agonist and antagonist. Clin Sci (Lond) 90 2 (1996) 91-96
30. Lagerstrom M.C., and Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7 4 (2008) 339-357
31. Ng G.Y., Clark J., Coulombe N., et al. Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem 274 12 (1999) 7607-7610
32. Prinster S.C., Hague C., and Hall R.A. Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57 3 (2005) 289-298
33. Rozenfeld R., Decaillot F.M., IJzerman A.P., et al. Heterodimers of G protein-coupled receptors as novel and distinct drug targets. Drug Discov Today Ther Strateg 3 4 (2006) 437-443
34. Clozel M., and Gray G.A. Are there different ETB receptors mediating constriction and relaxation?. J Cardiovasc Pharmacol 26 Suppl. 3 (1995) S262-S264
35. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2 4 (2001) 274-286
36. Harada N., Himeno A., Shigematsu K., et al. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. Cell Mol Neurobiol 22 2 (2002) 207-226
37. Gregan B., Jurgensen J., Papsdorf G., et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279 26 (2004) 27679-27687
38. Remuzzi G., Perico N., and Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 1 12 (2002) 986-1001
39. Sato K., Oka M., Hasunuma K., et al. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269 5 Pt 1 (1995) L668-L672
40. Jasmin J.F., Lucas M., Cernacek P., et al. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103 2 (2001) 314-318
41. Sauvageau S., Thorin E., Caron A., et al. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231 6 (2006) 840-846
42. Cardillo C., Kilcoyne C.M., Waclawiw M., et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33 2 (1999) 753-758
43. Shi-Wen X., Denton C.P., Dashwood M.R., et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116 3 (2001) 417-425
44. Dumont A.S., Lovren F., McNeill J.H., et al. Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits. J Neurosurg 94 2 (2001) 281-286
45. Rondelet B., Kerbaul F., Motte S., et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107 9 (2003) 1329-1335
46. Chen S.J., Chen Y.F., Meng Q.C., et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79 6 (1995) 2122-2131
47. Finsnes F., Skjonsberg O.H., Tonnessen T., et al. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 155 4 (1997) 1404-1412
48. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 9288 (2001) 1119-1123
49. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002) 896-903
50. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 23 (2008) 3010-3019
51. Letairis (ambrisentan) tablets [package insert] (2008), Gilead Sciences, Inc., Foster City, CA
52. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 4 (2004) 441-447
53. Barst R.J., Langleben D., Badesch D.B., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
54. Liu C., and Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 3 (2006) CD004434
55. Dupuis J., and Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31 2 (2008) 407-415
56. Segal E.S., Valette C., Oster L., et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 28 11 (2005) 971-980
57. Humbert M., Segal E.S., Kiely D.G., et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30 2 (2007) 338-344
58. Battistini B., Berthiaume N., Kelland N.F., et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 231 6 (2006) 653-695
59. Tracleer (bosentan) tablets [package insert] (2007), Actelion Pharmaceuticals, Inc., San Francisco, CA
60. Kapur S., and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158 3 (2001) 360-369
61. Schirger J.A., Chen H.H., Jougasaki M., et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation 109 2 (2004) 249-254
62. Wong S., Brennan F.E., Young M.J., et al. A direct effect of aldosterone on endothelin-1 gene expression in vivo. Endocrinology 148 4 (2007) 1511-1517
63. Ikebe M., Nonoguchi H., Nakayama Y., et al. Regulation of endothelin-converting enzyme 1 in nephrotic syndrome in rats. Nephron Exp Nephrol 94 4 (2003) e137-e145
64. Dhaun N., Pollock D.M., Goddard J., et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28 11 (2007) 573-579
65. Wu C., Chan M.F., Stavros F., et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40 11 (1997) 1690-1697